Cargando…
PD‐L1 and beyond: Immuno‐oncology in cytopathology
Over the past decade, immunotherapy has emerged as one of the most promising cancer treatments. Several monoclonal antibodies targeting the programmed death 1 (PD‐1)/ programmed death ligand‐1 (PD‐L1) pathway have been integrated into standard‐of‐care treatments for a wide range of cancer types. Alt...
Autores principales: | Iaccarino, Antonino, Salatiello, Maria, Migliatico, Ilaria, De Luca, Caterina, Gragnano, Gianluca, Russo, Maria, Bellevicine, Claudio, Malapelle, Umberto, Troncone, Giancarlo, Vigliar, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453493/ https://www.ncbi.nlm.nih.gov/pubmed/33955097 http://dx.doi.org/10.1111/cyt.12982 |
Ejemplares similares
-
Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer
por: Pisapia, Pasquale, et al.
Publicado: (2021) -
Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic
por: Palladino, Raffaele, et al.
Publicado: (2020) -
Cytology in the time of coronavirus disease (COVID-19): an Italian perspective
por: Vigliar, Elena, et al.
Publicado: (2021) -
KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
por: Nacchio, Mariantonia, et al.
Publicado: (2020) -
BRAF: A Two-Faced Janus
por: Pisapia, Pasquale, et al.
Publicado: (2020)